Consolidated Portfolio Review Corp’s Pfizer PFE Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-143,479	Closed	-$3.66M	–	287
2025 Q3	$3.66M	Sell	143,479 -4,642	-3%	-$115K	0.46%	52
2025 Q2	$3.59M	Buy	148,121 +267	+0.2%	+$6.23K	0.5%	51
2025 Q1	$3.75M	Buy	147,854 +27,541	+23%	+$721K	0.6%	41
2024 Q4	$3.19M	Buy	+120,313	New	+$3.26M	0.51%	46
2024 Q1	–	Sell	-10,970	Closed	-$316K	–	313
2023 Q4	$316K	Sell	10,970 -2,263	-17%	-$68.4K	0.07%	227
2023 Q3	$439K	Sell	13,233 -447	-3%	-$15.8K	0.11%	182
2023 Q2	$502K	Buy	13,680 +572	+4%	+$22.3K	0.12%	162
2023 Q1	$535K	Buy	+13,108	New	+$566K	0.14%	150

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Consolidated Portfolio Review Corp's PFE Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Pfizer (PFE) in Q4 2025, closing a stake of 143,479 shares — an estimated $3.66M sold.

Consolidated Portfolio Review Corp first reported a position in PFE in Q1 2023 and held it in 8 quarters. The position peaked at $3.75M in Q1 2025. 2,906 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

Consolidated Portfolio Review Corp reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
Consolidated Portfolio Review Corp sold 143,479 Pfizer shares in Q4 2025, an estimated $3.66M.
Consolidated Portfolio Review Corp first reported a position in Pfizer in Q1 2023 and held it in 8 quarters.
Consolidated Portfolio Review Corp's Pfizer position peaked at $3.75M in Q1 2025.
2,906 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.